

# How to Improve the Results of Treatment of Acute Pneumonia with Aggressive Development

Igor Klepikov\*

2116, NE, 27 st., Renton, WA, 98056, USA

\*Corresponding author: Igor Klepikov, 2116, NE, 27 st., Renton, WA, 98056, USA, Tel: +12069209643; E-mail: igor.klepikov@yahoo.com

Received date: March 26, 2018; Accepted date: March 28, 2018; Published date: March 31, 2018

Copyright: © 2018 Klepikov I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Klepikov I (2018) How to Improve the Results of Treatment of Acute Pneumonia with Aggressive Development. J Med Res Health Educ. Vol.2 No. 1: 7.

## Letter to the Editor

The World Health Organization (WHO) spent \$39 billion in 2010-2015 on the problem of acute pneumonia (AP) in children [1]. If this expensive programme had produced significant results, we would have known it from all the media. However, the results of this completed programme are not advertised and AP remains (again according to WHO statistics) one of the leading causes of morbidity and mortality in all age groups [2].

The unsatisfactory content of global statistics can be attributed to the high proportion of developing countries on the common list. After all, it is well known that high levels of health care require high financial costs and social maturity of society, while financial, economic and social problems in developing countries do not allow many medical achievements to be realized.

But the paradox of the problem is that expert evaluation should raise more serious concerns about the results of AP treatment in developed countries. Against the background of success and achievements in various fields of medicine, the best health systems of advanced countries cannot prevent the continued increase in the number of purulent complications of AP and offer real solutions to the problem.

The proportion of patients with pleural complications of AP is characterized by stable growth over the past two decades in the US and Europe [3-6]. High hopes for the so-called vaccination against pneumonia did not materialize. Moreover, contrary to expectations, the number of patients with pleural empyema increased statistically significantly after the beginning of total vaccination [7,8].

And the saddest and disturbing facts are not so much the current results of AP treatment, as the lack of convincing scientific explanations of observed trends and reasoned plans to address this problem.

I would like to draw your attention to the fact that the guaranteed prevention of purulent and destructive complications of AP is quite real, but its solution lies in another plane. This work was not only performed by the author of

these lines, but also underwent clinical testing with excellent results. The study was originally published in Russian [9].

Only recently, the author developed time and facilities for the translation and publication of the results obtained in the English language. The interest in the offered materials and their demand in the publishing industry exceeded expectations. During the last year, a detailed description of the research was presented in a separate book [10], and parts of this work published in more than 20 articles. The main list of these publications is presented below [11-29].

However, numerous publications can only give an informational result and have no impact on the current process of care for patients with AP. Moreover, specific patients with AP and their relatives are not interested in the theoretical aspects of the problem, but only the immediate results of a rapid cure for this disease without any complications. Knowing about the real possibility to avoid purulent and destructive complications of AP, to reduce the time and cost of treatment of such patients, it is impossible to remain a passive observer.

It is important to note that the proposed AP doctrine and the resulting treatment approaches do not require the development of new drugs or significant additional funding. It is necessary only in accordance with the legislative requirements of specific government bodies and commissions to conduct the necessary testing and approval of other approaches to the treatment of AP and change the curriculum of training doctors in this section. The implementation of these plans will spread the gains already made, but the formal application of these results will require the assistance of specialists in administrative and legal work.

In this regard, this manuscript is an appeal to a wide range of professionals who have both direct and indirect relation to the problem of inflammatory lung diseases. The implementation of the proposed project is necessary primarily for future patients with AP. That is why I very much count on professional support and real assistance in promoting this prospect.

## References

1. World Health Organization (2009) New WHO/UNICEF action plan to tackle pneumonia, Available from: [http://www.who.int/maternal\\_child\\_adolescent/news\\_events/news/2009/02\\_11\\_09/en/](http://www.who.int/maternal_child_adolescent/news_events/news/2009/02_11_09/en/) Accessed on: November 2, 2009.
2. World Health Organization (2016) Pneumonia, Available from: <http://www.who.int/mediacentre/factsheets/fs331/en/> Accessed on: September 18, 2016.
3. Principi N, Esposito S (2011) Management of severe community-acquired pneumonia of children in developing and developed countries. *Thorax* 66: 815-822.
4. Jain S (2015) Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. *New England Journal of Medicine* 372: 835-845.
5. Elemraid MA (2015) Risk factors for the development of pleural empyema in children. *Pediatric Pulmonology* 50: 721-726.
6. Restrepo R, Marcos I, Faverio P, Anzueto A (2013) Long-Term Prognosis in Community-Acquired Pneumonia. *Current Opinion in Infectious Diseases* 26: 151-158.
7. Li ST, Tancredi DJ (2010) Empyema Hospitalizations Increased in US Children Despite Pneumococcal Conjugate Vaccine. *Pediatrics* Vol. 125.
8. Ampofo K, Pavia AT, Stockmann CR, Blaschke AJ, Weng HY, et al. (2011) Evolution of the epidemiology of pneumococcal disease among Utah children through the vaccine era. *Pediatr Infect Dis J* 30: 1100-1113.
9. Klepikov I (1989) Acute pneumonia and its purulent and destructive complications in children in the midst of a major industrial centre of Western Siberia. Dissertation for the Degree of Doctor of Medical Sciences, Leningrad.
10. Klepikov I (2017) Acute pneumonia: a new look at the old problem. Lambert Academic Publishing, Latvia.
11. Klepikov I (2017) Acute Pneumonia in Children: The Price of Illusions and Delusions. *J Pediatr Care* 3: 1.
12. Klepikov I (2017) The Effect of Intravenous Infusion on the Dynamics of Acute Pneumonia. *EC Pulmonology and Respiratory Medicine* 4: 15-20.
13. Klepikov I (2017) The Meaning of Pulmonary Reflexes in the Pathogenesis of Acute Pneumonia. *Intern Med* 7: 232.
14. Klepikov I (2017) Why Need a New Concept of Acute Pneumonia. *J Tradit Med Clin Natur* 6: 212.
15. Klepikov I (2017) The Role of Cardiovascular Disorders in the Pathogenesis of Acute Pneumonia. *J Cardiol and Cardiovasc Ther* 4: 555628.
16. Klepikov I (2017) Can we Reduce the Cost of Treatment of Acute Pneumonia?. *Mod Appl Bioequiv Availab* 1: 555551.
17. Klepikov I (2017) Acute Pneumonia in Children - Illness or Infection? - Open Letter to the Editorial Staff. *J Infect Non Infect Dis* 3: 022.
18. Klepikov I (2017) The New Doctrine of Acute Pneumonia-the Key to Solve the Problem- Open Letter to the Editorial Staff. *EC Paediatrics* 4: 138-139.
19. Klepikov I (2017) Cupping therapy in the 21st century-Why not!?. *Journal of General and Emergency Medicine* 2: 28.
20. Klepikov I (2017) Acute pneumonia: current state of the problem and its solutions. *Journal of Oral Care and Dentistry* Vol. 1.
21. Klepikov I (2017) Guarantee the Prevention of Purulent Complications of Acute Pneumonia is a Reality. *EC Paediatrics* 5: 152-153.
22. Klepikov I (2017) Is it Possible to Create a Universal Cure for Pneumonia? *J Pulm Med Respir Res* 3: 013.
23. Klepikov I (2017) Tablet against Pneumonia- Letter to Editor. *Am J Drug Deliv* 5: 009-010.
24. Klepikov I (2017) Again on the Tablet Against Pneumonia. *EC Pulmonology and Respiratory Medicine* 5: 213-215.
25. Klepikov I (2017) Acute Pneumonia as a Reflection of the Unity and Struggle of Two Biological Systems (Some Facts and Axioms). *EC Pulmonology and Respiratory Medicine SI.01:* 01-05.
26. Klepikov I (2017) Acute Pneumonia: Infection or Disease?. *Examines Phy Med Rehab* 1: EPMR.000509.
27. Klepikov I (2017) How to Prevent the Development of Purulent Complications of Acute Pneumonia. *J Head Neck Spine Surg* 1: 555561.
28. Klepikov I (2018) First Aid for Aggressive Forms of Acute Pneumonia. *EC Pulmonology and Respiratory Medicine* 7: 34-37.
29. Klepikov I (2018) Cupping Therapy as a means of First Aid in Acute Pneumonia. *J Clin Case Study*.